Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Medicina Clínicaarrow_drop_down
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Medicina Clínica
Article . 2014 . Peer-reviewed
License: Elsevier TDM
Data sources: Crossref
versions View all 1 versions
addClaim

Indicaciones terapéuticas actuales de la talidomida y la lenalidomida

Authors: Josep Ordi-Ros; Francisco Javier Cosiglio;

Indicaciones terapéuticas actuales de la talidomida y la lenalidomida

Abstract

Resumen La talidomida es un derivado sintetico del acido glutamico, introducido por primera vez en Alemania en 1956 como un medicamento de venta sin receta. La aprobacion fue como sedante seguro, incluso a pequenas dosis, no adictivo y sin efectos secundarios tales como debilidad motora, pero fue retirada de la circulacion por asociarse a graves malformaciones en recien nacidos. Mas tarde, la Food and Drug Administration aprobo su uso en el tratamiento del eritema nudoso leproso y tambien demostro eficacia en otros procesos dermatologicos refractarios tales como el prurigo actinico, la histiocitosis de Langerhans del adulto, la estomatitis aftosa, el sindrome de Behcet, la enfermedad del injerto contra el huesped, la sarcoidosis cutanea, el eritema multiforme, la infiltracion cutanea linfocitaria de Jessner-Kanof, el sarcoma de Kaposi, el liquen plano, el lupus eritematoso sistemico, el melanoma, el prurigo nodular, el pioderma gangrenoso y otros. En mayo de 2006 fue aprobada para el tratamiento del mieloma multiple. Nuevos analogos de la talidomida, como la lenalidomida, han sido desarrollados, aunque con escasa experiencia clinica. Este trabajo es una revision de la historia, farmacologia, mecanismo de accion, usos clinicos y efectos adversos de la talidomida y sus analogos.

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    6
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Top 10%
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
6
Average
Top 10%
Average
Upload OA version
Are you the author of this publication? Upload your Open Access version to Zenodo!
It’s fast and easy, just two clicks!